TY - JOUR
T1 - A circulating miRNA assay as a first-line test for prostate cancer screening
AU - Sharova, Evgeniya
AU - Grassi, Angela
AU - Marcer, Anna
AU - Ruggero, Katia
AU - Pinto, Francesco
AU - Bassi, Pierfrancesco
AU - Zanovello, Paola
AU - Zattoni, Filiberto
AU - D'Agostino, Donna M
AU - Iafrate, Massimo
AU - Ciminale, Vincenzo
PY - 2016
Y1 - 2016
N2 - Prostate cancer (PCa) screening currently relies on prostate-specific antigen (PSA) testing and digital rectal examination. However, recent large-scale studies have questioned the long-term efficacy of these tests, and biomarkers that accurately identify PCa are needed.\r\nMETHODS:\r\nWe analysed the levels of circulating microRNAs (miRNAs) in patients with elevated PSA who were diagnosed with either localised PCa (n=36) or benign prostatic hyperplasia (BPH, n=31) upon biopsy. Real-time RT-PCR with Taqman probes was used to measure plasma levels of miRNAs. To circumvent problems associated with circulating miRNA quantitation, we computed the expression ratios of upregulated and downregulated miRNAs.\r\nRESULTS:\r\nThe miR-106a/miR-130b and miR-106a/miR-223 ratios were significantly different between the biopsy-positive and BPH groups (P<0.0001), and yielded statistical power values that were >0.99. Both miRNA ratios were highly sensitive and more specific than PSA in discriminating localised PCa from BPH. Receiver operating characteristic curve analysis revealed area under curve values of 0.81 (miR-106a/miR-130b) and 0.77 (miR-106a/miR-223).\r\nCONCLUSIONS:\r\nTesting for circulating miR-106a/miR-130b and miR-106a/miR-223 ratios may reduce the costs and morbidity of unnecessary biopsies and is feasible for large-scale screening, as it requires measuring only three miRNAs.
AB - Prostate cancer (PCa) screening currently relies on prostate-specific antigen (PSA) testing and digital rectal examination. However, recent large-scale studies have questioned the long-term efficacy of these tests, and biomarkers that accurately identify PCa are needed.\r\nMETHODS:\r\nWe analysed the levels of circulating microRNAs (miRNAs) in patients with elevated PSA who were diagnosed with either localised PCa (n=36) or benign prostatic hyperplasia (BPH, n=31) upon biopsy. Real-time RT-PCR with Taqman probes was used to measure plasma levels of miRNAs. To circumvent problems associated with circulating miRNA quantitation, we computed the expression ratios of upregulated and downregulated miRNAs.\r\nRESULTS:\r\nThe miR-106a/miR-130b and miR-106a/miR-223 ratios were significantly different between the biopsy-positive and BPH groups (P<0.0001), and yielded statistical power values that were >0.99. Both miRNA ratios were highly sensitive and more specific than PSA in discriminating localised PCa from BPH. Receiver operating characteristic curve analysis revealed area under curve values of 0.81 (miR-106a/miR-130b) and 0.77 (miR-106a/miR-223).\r\nCONCLUSIONS:\r\nTesting for circulating miR-106a/miR-130b and miR-106a/miR-223 ratios may reduce the costs and morbidity of unnecessary biopsies and is feasible for large-scale screening, as it requires measuring only three miRNAs.
KW - prostate cancer screening
KW - prostate cancer screening
UR - https://publicatt.unicatt.it/handle/10807/81885
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84969972519&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84969972519&origin=inward
U2 - 10.1038/bjc.2016.151
DO - 10.1038/bjc.2016.151
M3 - Article
SN - 0007-0920
VL - 114
SP - 1362-6-1366
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 12
ER -